Transplacental transfer of the opioid growth factor, [Met5]-enkephalin, in rats

Ian Zagon, James D. Wylie, W. Jeffrey Hurst, Patricia McLaughlin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Placental transfer of the pentapeptide [Met5]-enkephalin, known to function as a growth regulating factor and neuromodulatory agent, was studied in pregnant Sprague-Dawley rats. Using separation by reversed phase high-performance liquid chromatography, and analysis by derivative spectroscopy, [Met5]-enkephalin was detected in 20-day-old fetal tissue including brain, heart, lung, and kidney. Fetal tissues from pregnant rats given an injection of 40 mg/kg [Met5]-enkephalin on gestation day 20 had markedly elevated levels of peptide within 1 h, indicating the transplacental transfer of this opioid. [Met5]-enkephalin levels were increased from control samples at 1, 2, 4, and 14 h post-injection of peptide, but not at 24 h. Evaluation of breakdown products of [Met5]-enkephalin, along with the related peptide [Leu5]-enkephalin, revealed that elution times differed substantially from [Met5]-enkephalin. These data indicate that [Met5]-enkephalin is present in fetal organs, crosses the placenta, does not appear to be restrictive in organ specificity, and is sustained in fetal tissues at detectable levels for at least 14 h. Given that [Met5]-enkephalin tonically inhibits DNA synthesis in the fetus, these results raise the question of whether an elevated level of this peptide (either maternally or from the fetus) may be detrimental to cellular ontogeny in the fetus, and perhaps have long-term implications for postnatal development.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalBrain Research Bulletin
Volume55
Issue number3
DOIs
StatePublished - Aug 20 2001

Fingerprint

Enkephalins
Opioid Analgesics
Intercellular Signaling Peptides and Proteins
Fetus
Peptides
Organ Specificity
Injections
Reverse-Phase Chromatography
Placenta
Sprague Dawley Rats
Spectrum Analysis
High Pressure Liquid Chromatography
Kidney
Pregnancy
Lung
DNA
Brain

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

@article{51c26fd1a2ba4f4e887ee33e4c7d09d2,
title = "Transplacental transfer of the opioid growth factor, [Met5]-enkephalin, in rats",
abstract = "Placental transfer of the pentapeptide [Met5]-enkephalin, known to function as a growth regulating factor and neuromodulatory agent, was studied in pregnant Sprague-Dawley rats. Using separation by reversed phase high-performance liquid chromatography, and analysis by derivative spectroscopy, [Met5]-enkephalin was detected in 20-day-old fetal tissue including brain, heart, lung, and kidney. Fetal tissues from pregnant rats given an injection of 40 mg/kg [Met5]-enkephalin on gestation day 20 had markedly elevated levels of peptide within 1 h, indicating the transplacental transfer of this opioid. [Met5]-enkephalin levels were increased from control samples at 1, 2, 4, and 14 h post-injection of peptide, but not at 24 h. Evaluation of breakdown products of [Met5]-enkephalin, along with the related peptide [Leu5]-enkephalin, revealed that elution times differed substantially from [Met5]-enkephalin. These data indicate that [Met5]-enkephalin is present in fetal organs, crosses the placenta, does not appear to be restrictive in organ specificity, and is sustained in fetal tissues at detectable levels for at least 14 h. Given that [Met5]-enkephalin tonically inhibits DNA synthesis in the fetus, these results raise the question of whether an elevated level of this peptide (either maternally or from the fetus) may be detrimental to cellular ontogeny in the fetus, and perhaps have long-term implications for postnatal development.",
author = "Ian Zagon and Wylie, {James D.} and Hurst, {W. Jeffrey} and Patricia McLaughlin",
year = "2001",
month = "8",
day = "20",
doi = "10.1016/S0361-9230(01)00518-4",
language = "English (US)",
volume = "55",
pages = "341--346",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "3",

}

Transplacental transfer of the opioid growth factor, [Met5]-enkephalin, in rats. / Zagon, Ian; Wylie, James D.; Hurst, W. Jeffrey; McLaughlin, Patricia.

In: Brain Research Bulletin, Vol. 55, No. 3, 20.08.2001, p. 341-346.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transplacental transfer of the opioid growth factor, [Met5]-enkephalin, in rats

AU - Zagon, Ian

AU - Wylie, James D.

AU - Hurst, W. Jeffrey

AU - McLaughlin, Patricia

PY - 2001/8/20

Y1 - 2001/8/20

N2 - Placental transfer of the pentapeptide [Met5]-enkephalin, known to function as a growth regulating factor and neuromodulatory agent, was studied in pregnant Sprague-Dawley rats. Using separation by reversed phase high-performance liquid chromatography, and analysis by derivative spectroscopy, [Met5]-enkephalin was detected in 20-day-old fetal tissue including brain, heart, lung, and kidney. Fetal tissues from pregnant rats given an injection of 40 mg/kg [Met5]-enkephalin on gestation day 20 had markedly elevated levels of peptide within 1 h, indicating the transplacental transfer of this opioid. [Met5]-enkephalin levels were increased from control samples at 1, 2, 4, and 14 h post-injection of peptide, but not at 24 h. Evaluation of breakdown products of [Met5]-enkephalin, along with the related peptide [Leu5]-enkephalin, revealed that elution times differed substantially from [Met5]-enkephalin. These data indicate that [Met5]-enkephalin is present in fetal organs, crosses the placenta, does not appear to be restrictive in organ specificity, and is sustained in fetal tissues at detectable levels for at least 14 h. Given that [Met5]-enkephalin tonically inhibits DNA synthesis in the fetus, these results raise the question of whether an elevated level of this peptide (either maternally or from the fetus) may be detrimental to cellular ontogeny in the fetus, and perhaps have long-term implications for postnatal development.

AB - Placental transfer of the pentapeptide [Met5]-enkephalin, known to function as a growth regulating factor and neuromodulatory agent, was studied in pregnant Sprague-Dawley rats. Using separation by reversed phase high-performance liquid chromatography, and analysis by derivative spectroscopy, [Met5]-enkephalin was detected in 20-day-old fetal tissue including brain, heart, lung, and kidney. Fetal tissues from pregnant rats given an injection of 40 mg/kg [Met5]-enkephalin on gestation day 20 had markedly elevated levels of peptide within 1 h, indicating the transplacental transfer of this opioid. [Met5]-enkephalin levels were increased from control samples at 1, 2, 4, and 14 h post-injection of peptide, but not at 24 h. Evaluation of breakdown products of [Met5]-enkephalin, along with the related peptide [Leu5]-enkephalin, revealed that elution times differed substantially from [Met5]-enkephalin. These data indicate that [Met5]-enkephalin is present in fetal organs, crosses the placenta, does not appear to be restrictive in organ specificity, and is sustained in fetal tissues at detectable levels for at least 14 h. Given that [Met5]-enkephalin tonically inhibits DNA synthesis in the fetus, these results raise the question of whether an elevated level of this peptide (either maternally or from the fetus) may be detrimental to cellular ontogeny in the fetus, and perhaps have long-term implications for postnatal development.

UR - http://www.scopus.com/inward/record.url?scp=0034899183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034899183&partnerID=8YFLogxK

U2 - 10.1016/S0361-9230(01)00518-4

DO - 10.1016/S0361-9230(01)00518-4

M3 - Article

C2 - 11489341

AN - SCOPUS:0034899183

VL - 55

SP - 341

EP - 346

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 3

ER -